May 11, 2020 / 12:49 PM / 18 days ago

BRIEF-Appili Therapeutics Submits CTA With Health Canada

May 11 (Reuters) - Appili Therapeutics Inc:

* APPILI THERAPEUTICS SUBMITS CTA WITH HEALTH CANADA TO SPONSOR PROPHYLACTIC PHASE 2 CLINICAL TRIAL EVALUATING FUJIFILM TOYAMA CHEMICAL’S FAVIPIRAVIR AS A PREVENTATIVE MEASURE AGAINST COVID-19 IN CANADIAN LONG-TERM CARE FACILITIES

* APPILI THERAPEUTICS INC - CLINICAL PROGRAM DESIGNED TO ASSESS USE OF FAVIPIRAVIR FOR COVID-19 AS PROPHYLAXIS FOR OUTBREAK CONTROL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below